Technologies & Platforms
WuXi Biologics is committed to providing open-access technology platforms so that any company anywhere can efficiently and cost effectively bring new medicines to patients worldwide. Our technology platforms span the entire discovery to manufacturing spectrum.
WuXi Biologics offers five advanced platforms for discovery of antibody-based therapeutics and we leverage these platforms individually or combined to find the ideal therapeutic antibody.
- Advanced Hybridoma System
- Phage Display
- OMT Technology
- Bispecific Antibodies
- Antibody Drug Conjugates
Cell Line Development
Multiple cell line platforms are available using industry standard technologies to keep your drug development costs low and to allow ultimate flexibility for cell line use in the production of protein therapeutics. In addition, WuXi has engineered its own proprietary CHOK1 system.
Cell Culture Development and Manufacturing
WuXi Biologics utilizes three different cell culture technologies that can be used as a standard platform process or customized to meet your protein production requirements.
- Fed-batch using single-use disposable bioreactors (up to 2,000 L)
- Concentrated Fed-batch approach to deliver higher yields per run
- Perfusion cell culture utilizing The ATF™ System technology
Over thirty different cell-based functional/potency assays have been developed for our clients by our 20+ team of bioassay experts. Included are patent pending ADCC and CDC assays.
Drug Product Fill & Finish
WuXi provides parental drug product fill & finish into multiple container and closure configurations utilizing state-of-the-art filling systems. Pre-filled syringe filling lines will be available in late 2016.